NFC
OCUL icon

Northeast Financial Consultants’s Ocular Therapeutix OCUL Stock Holding History

Northeast Financial Consultants’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12,483
Closed -$52K – 344
2022
Q3 		$52K Hold
12,483
– – ﹤0.01% 329
2022
Q2 		$50K Hold
12,483
– – ﹤0.01% 324
2022
Q1 		$62K Sell
12,483
-1,532
-11% -$8.49K ﹤0.01% 383
2021
Q4 		$98K Hold
14,015
– – 0.01% 350
2021
Q3 		$140K Buy
+14,015
New +$157K 0.01% 342

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northeast Financial Consultants's OCUL Position: Q4 2022 in Review

Northeast Financial Consultants sold out of Ocular Therapeutix (OCUL) in Q4 2022, closing a stake of 12,483 shares — an estimated $52K sold.

Northeast Financial Consultants first reported a position in OCUL in Q3 2021 and held it in 5 quarters. The position peaked at $140K in Q3 2021. 116 funds tracked by Wall St. Rank hold OCUL as of Q4 2022.

  • Northeast Financial Consultants reported no remaining Ocular Therapeutix position as of Q4 2022 after selling out during the quarter.
  • Northeast Financial Consultants sold 12,483 Ocular Therapeutix shares in Q4 2022, an estimated $52K.
  • Northeast Financial Consultants first reported a position in Ocular Therapeutix in Q3 2021 and held it in 5 quarters.
  • Northeast Financial Consultants's Ocular Therapeutix position peaked at $140K in Q3 2021.
  • 116 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2022.

Based on Northeast Financial Consultants's 13F filing for Q4 2022, filed 13 Feb 2023.